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Calculation of the disease burden
associated with environmental chemical
exposures: application of toxicological
information in health economic estimation
Philippe Grandjean1,2* and Martine Bellanger3
Abstract
Calculation of costs and the Burden of Disease (BoD) is useful in developing resource allocation and prioritization
strategies in public and environmental health. While useful, the Disability-Adjusted Life Year (DALY) metric
disregards subclinical dysfunctions, adheres to stringent causal criteria, and is hampered by gaps in environmental
exposure data, especially from industrializing countries. For these reasons, a recently calculated environmental BoD
of 5.18% of the total DALYs is likely underestimated. We combined and extended cost calculations for exposures to
environmental chemicals, including neurotoxicants, air pollution, and endocrine disrupting chemicals, where
sufficient data were available to determine dose-dependent adverse effects. Environmental exposure information
allowed cost estimates for the U.S. and the EU, for OECD countries, though less comprehensive for industrializing
countries. As a complement to these health economic estimations, we used attributable risk valuations from expert
elicitations to as a third approach to assessing the environmental BoD. For comparison of the different estimates,
we used country-specific monetary values of each DALY. The main limitation of DALY calculations is that they are
available for few environmental chemicals and primarily based on mortality and impact and duration of clinical
morbidity, while less serious conditions are mostly disregarded. Our economic estimates based on available
exposure information and dose-response data on environmental risk factors need to be seen in conjunction
with other assessments of the total cost for these environmental risk factors, as our estimate overlaps only slightly
with the previously estimated environmental DALY costs and crude calculations relying on attributable risks for
environmental risk factors. The three approaches complement one another and suggest that environmental
chemical exposures contribute costs that may exceed 10% of the global domestic product and that current DALY
calculations substantially underestimate the economic costs associated with preventable environmental risk factors.
By including toxicological and epidemiological information and data on exposure distributions, more representative
results can be obtained from utilizing health economic analyses of the adverse effects associated with
environmental chemicals.
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Background
To guide the most efficient use of limited resources for
the purpose of reducing major origins of death and dis-
ability, researchers have attempted to estimate burdens of
disease and catalogued them by risk factors. The first cal-
culations of the global burden of disease were released in
the World Development Report in 1993 [1]. The common
metric most often used in measuring the Global Burden
of Disease (GBD) is the Disability-Adjusted Life Year
(DALY) [2], which combines duration and quality of life
into a common metric that can be applied across diseases
and organ systems (Fig. 1).
DALY calculations have proven highly useful for com-
parisons of the relative importance of major diseases and
risk factors. Yet, the data available have so far allowed
separation only of a limited number of risk factors and
etiologies and have required merging some of them into
clusters [3]. For example, the 2013 GBD report concluded
that elevated blood pressure was the largest contributor to
lost DALYs globally, while increased body mass index was
the third largest contributor [3]. Both conditions likely
represent intermediate steps in the pathogenesis of dis-
ease, and current evidence suggests that industrial chemi-
cals may contribute to disease causation via hypertension
and/or obesity [4–7].
An overall limiting factor is that calculations require
decisions on causal associations, distributions of ex-
posure to each risk factor in global populations and
estimation of etiological effect sizes and disabilities
[8]. The exact algorithm and the complex computa-
tions of the GBD also make it difficult to assess the
validity of the summary estimates, which may cause
disagreement [9]. Thus, apart from sources of infec-
tious disease risks, the 2013 GBD report [3] estimated
environmentally-attributable DALYs lost only for
certain occupational hazards, ambient air pollution,
household air pollution from solid fuel burning, resi-
dential exposure to radon, and childhood lead expos-
ure. In total, the selected environmental risk factors
contributed about 127 million DALYs or 5.18% of all
DALYs lost [3]. Although substantial knowledge gaps
remain, preventable environmental chemical expo-
sures are known to include pesticides [10] and
arsenic-contaminated drinking water [11] as major
contributors to ill health on a global scale. However,
these risks are not yet included in the GBD assess-
ment. In addition, industrial chemicals can contribute
to disease and dysfunctions, for example, by interfer-
ing with hormonal functions (endocrine disrupting
chemicals, or EDCs) [12, 13]. Further, adverse effects
on brain development due to lead, methylmercury and
other neurotoxicants have been highlighted as major
societal costs, even in the absence of diagnosed neuro-
psychiatric disease [14–16].
This review therefore seeks to identify approaches
that can be used to complement the existing DALY cal-
culations by assessing adverse health effects from avail-
able data on exposure levels and exposure-response
relationships, while taking into account known uncer-
tainties. We illustrate how health economic methods
can be utilized to document the value of preventing
subclinical functional changes that are not readily
expressed in terms of DALYs. For these comparisons,
we apply country-specific economic values of a DALY
so that the toxicology-based economic estimates can be
compared to DALY losses (Fig. 1).
Toxicology-based health economics approach
Among the methods that may be applied to estimate
the environmental burden of diseases (BoD), this art-
icle focuses on using assessments of environmental
chemical exposures in combination with the economic
value of environmentally-related adverse health out-
comes. We then compare the economic estimates of
health impacts that include subclinical functional
changes for several major types of exposures with suf-
ficient data for this kind of analysis. To the extent
possible, these results are compared with the less ex-
tensive DALY estimates.
To ensure the widest possible coverage of our work,
we searched the PubMed database for studies and re-
ports published in English from 2000 to 2015 using
terms including “cost” or “economic” in combination
with the terms “environmental” or “chemical” and “im-
pact” or “exposure.” We also searched cited references
to identify additional relevant papers not retrieved by
this search. In addition, we searched the websites of
Eurostat, the Organization for Economic Cooperation
Fig. 1 For individual environmental risks, the costs of exposure-
dependent adverse effects can be estimated using health economics
methods, and they can then be compared to costs associated with the
estimated disease burden in terms of disability adjusted life years
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and Development (OECD) and the World Health
Organization (WHO).
Attributing disease burdens to environmental exposures
As recommended by the Institute of Medicine, the BoD
attributable to an environmental risk factor can be calcu-
lated as a product of three factors [17]:
Disease burden ¼ Disease rate x AF x Population size
where AF is the Attributable Fraction (i.e., the percent-
age of a particular disease category that would be elimi-
nated if the environmental risk factor were reduced to
its lowest feasible level) [18]. The AF is the product of
the prevalence of a risk factor multiplied by the relative
risk of disease associated with that risk factor [19].
In considering exposure-outcome relationships, the
GBD project relies upon expert input to select those links
that meet stringent criteria for causality [3, 8]. A conse-
quence of this strategy is that it favors established causal
connections, for example, for infectious disease or injury,
and those that have been supported by randomized clin-
ical trials. In environmental health, intervention studies
are often too complex or long-lasting to provide necessary
documentation on the adverse impact of environmental
risk factors [20]. Although the BoD calculations require
knowledge on exposure-dependent outcomes and distri-
butions of exposures, it would not be appropriate to inter-
pret the absence of such information as support for an AF
of zero [21, 22], although this is commonly given as the
reason for not including such risk factors in BoD
estimates. In contrast, the Intergovernmental Panel on
Climate Change (IPCC) has prudently applied a weight-
of-evidence characterization for probability of causation
[23]. In dealing with thousands of potentially disease-
causing chemicals, a realistic and precautionary approach
would require characterization of the possible impact also
of those substances that have not yet proven to cause ad-
verse effects [21].
Expert elicitation methods have been developed to
achieve consensus on AFs, while taking into account
uncertainties regarding multifactorial causation and the
impact of individual environmental chemicals [24, 25].
For such purposes, the Delphi method was developed
on the premise that group judgments are more valid
than those of individuals [26, 27]. Both this approach
and expert elicitation have been applied by WHO to
provide quantitative estimates on the fractions of 85
diseases attributable to the environment. The WHO au-
thors considered that a total of 24% of the global BoD
were reasonably due to modifiable environmental risk
factors [28], with a more recent update resulting in a
22% contribution [29]. Although focusing mainly on
specific diseases and less clearly on subclinical
dysfunctions, the WHO estimate greatly exceeds the es-
timate of 5.18% in the GBD report [3].
Existing epidemiologic knowledge can be systematically
evaluated in regard to causal attributions using the rigor-
ous criteria developed by the GRADE Working Group
[30, 31]. This approach was recently applied by the WHO
in assessing disease causation by household fuel burning
[32]. To assess the plausibility of a causal association,
experimental toxicology information must similarly be
systematically evaluated, and criteria for this purpose have
been developed by the U.S. National Toxicology Program
[33], the Danish Environmental Protection Agency [34],
and several academic groups [35–37].
A recent project evaluated the impact of environmen-
tal exposures to EDCs within the EU [38], using the
IPCC methodology for assessment of causation [23],
the epidemiology criteria defined by the GRADE
Working Group [30, 31], and the Danish Environmen-
tal Protection Agency classification of the strength of
human and laboratory evidence for disease causation
[34]. Similar calculations were subsequently carried out
for the US [39], thereby contributing to a better cover-
age of global costs for the well-studied chemical risks.
Monetizing the environmentally-related health outcomes
The economic estimates associated with the exposure-
associated outcomes are typically calculated by the
human capital approach, as based on the indirect costs
[40, 41], i.e., the value of resources foregone and output
lost due to illness, such as lost earnings, along with the es-
timated direct costs from medical treatment, as assessed
by the Cost of Illness (CoI) method [42, 43]. The annual
costs (or lifetime costs) are then estimated. The human
capital approach provides important advantages, as it is
transparent and allows assessment of costs associated also
with regard to subclinical dysfunctions that may occur
without necessarily being linked to a formal medical diag-
nosis and treatment.
Economic losses due to dysfunctions, such as cogni-
tive deficits impacting productivity are generally calcu-
lated from projected life-time earnings converted to
present-day value by discounting, while taking into ac-
count the Purchasing Power Parity (PPP) [44]. Using
data relating intelligence quotient (IQ), labor force
participation and schooling, the economic cost of a lost
IQ point can be quantified through lost lifetime eco-
nomic productivity [44, 45]. Overall, a cognitive skill
improvement by one SD (i.e. 15 IQ points) is associated
with 12% and 16% increases in annual labor earnings in
high-income countries and low and middle-income
countries (LMICs), respectively [46]. On the standard
assumption that labor income represents half of the
Gross National Income (GNI), as based on the World
Bank World Development Indicators, the global
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economic loss associated with cognitive deficits can be
derived as a percentage of the GNI [47].
Overall, we assume a societal perspective, where all costs
borne by society are relevant (i.e., costs borne by the health
care system, by the individual and the household, and by
employers and insurers, as applicable). All estimates of eco-
nomic costs are given in $(US)2010, with value range [in
square brackets] from sensitivity analyses when available.
Additional results are provided to show percentages of the
global domestic product (GDP) or relative costs for given
countries or regions studied, also for the year 2010.
To quantify and compare the costs of adverse health end
points, the monetary value of a DALY or QALY (Quality-
Adjusted life years) needs to be ascertained. While no offi-
cial consensus of the appropriate value of a DALY/QALY
has been reached, a conversion based on the Value of Life
Year (VOLY) has been considered as the most reasonable
choice [48, 49]. Different Economic values of DALYs have
been allocated per income country group level, as defined
by the World Bank. We chose the median VOLY value of
$52,320 [$32,700 - $130,800], in terms of 2010 values ad-
justed for differences in per capita GINI 2010 at PPP and
for inflation, as the basis for the DALY value estimates [50].
Each DALY value per income group level was adjusted
based on the ratio of GNI per capita of the given group to
the GNI per capita of the EU 27 as follows:
DALY UV IC ¼ DALYUVEU 2010pppCGLi GNI per capita2010pppEU GNI per capita
with DALYUVICGi= Unit value for a DALY in the EU;
with CGLi = country group level i GNI per capita and i
= 1 to 5; CGL1 is for Low Income Country, CGL2 for
Lower Middle Income Country; CGL3 is for Upper Mid-
dle Income Country and CGL4for High Income Country;
and CGL5 includes all Low and Middle Income coun-
tries, since some environmental population attributable
fractions were available at that income level and for
High Income Countries.
Using the above dollar values, toxicology-based health
economics calculations can now be compared with pub-
lished DALY estimates (Fig. 1). Important groups of en-
vironmental chemicals of likely impact on the BoD
include neurotoxicants that impact human brain devel-
opment [16, 51], air pollution [52] and EDCs [12, 13].
Evidence on these substances is now reviewed to deter-
mine how future GBD calculations may more compre-
hensively consider BoD estimates that include wider
ranges of dysfunctions and groups of chemicals.
Estimates for major environmental risk factors
Lead and other neurotoxicants
The GBD report estimates the global burden due to lead
poisoning in terms of intellectual disabilities (or mental
retardation) [3], from which a global economic cost of
$5 [$3.15–$12.6] billion per year can be derived (Table 1).
However, this estimate does not consider IQ losses
within the normal range and, therefore, fails to capture
the societal losses for those children who are not shifted
into the subnormal range of cognitive function. A more
comprehensive assessment of children experiencing an
IQ loss from childhood lead exposure in LMICs alone
Table 1 Estimates of economic costs associated with lead and other neurotoxicant exposure
Risk factor Adverse consequences Context Economic cost ($billions) % GDP % of Global GDP
Lead exposure Cognitive deficits LMICs [53] 1040 [775.5–1237] 5.20 [3.9–6.2] 1.68 [1.25–1.99]
U.S. [57] 54.0 [47.5–64.3] 0.37 [0.33–0.44] 0.09 [0.08–0.1]
EU [82] 60.6 [53.7–72.2] 0.36 [0.32–0.43] 0.1 [0.09–0.12]
Total (sum) 1154 [876.7–1373.5] 2.47 [1.88–2.94] 1.83 [1.39–2.18]
Intellectual disability only World (WHO) [29] 16 [10–40] <0.01 <0.01
World (GDB) [3] 246 [154–615] 0.4 [0.24–1] 0.4 [0.24–1]
Neurotoxicity total World (WHO) [29] 5 [3.15–12.6] <0.01 <0.01
World (GBD) [3] 283 [177–708] 0.45 [0.27–1.1] 0.45 [0.27–1.1]
Methylmercury Cognitive deficits U.S. [58] 4·8 [4.2–5.7] 0.03 [0.026–0.04] <0.01
EU [56] 10.8 [9,6–11.2] 0.06 [0.053–0.062] <0.01
Sum 15.6 [13.8–16.9] 0.05 [0.044–0.54] <0.01
Organophosphate
pesticides
Cognitive deficits U.S. [39] 44.7 [14.6–59.5] 0.30 [0.1–0.4] 0.07 [0.2–0.09]
EU [69] 194 [62–259] 1.14 [0.37–1.52] 0.31 [0.09–0.4]
Sum 248.7 [76.6–318.5] 0.8 [0.25–1.02] 0.38 [0.11–0.49]
Polybrominated
diphenyl ethers
Cognitive deficits U.S. [39] 266 [133–367] 1.8 [0.9–2.5] 0.4 [0.2–0.6]
EU [69] 12·6 [2.08–29.4] 0.07 [0.011–0.16] 0.02 [0.003–0.05]
Sum 278.6 [135.08–396.4] 0.9 [0.43–1.28] 0.42 [0.23–0.65]
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suggested an economic cost of $1.04 [$0.776 – $1.237]
trillion from the sensitivity analysis [53], a value nearly
200-fold greater than the cost obtained from the GBD
approach.
An extended assessment suggests that the estimated
costs of cognitive impairment associated with known
childhood lead exposure represent about 1.83% [1.39% –
2.18%] of the global GDP in 2010 (Table 1), which is
more than 4-fold greater than the similar value for
DALYs valued by the GBD study (0.45%) [3] and by the
WHO (0.4%) [29]. An earlier estimate that relied on ex-
trapolation from US data suggested that the phase-out
of lead in petrol has resulted in global benefits of $2.45
trillion per year [54]. When using a country-specific
DALY value of $79,483 [49,677–198,798], this amount
corresponds to approximately 30 [12.5–50] million
DALYs, about three-fold higher than the estimate by the
GBD authors. Thus, although lead was included as an
environmental risk factor in the GBD report, the DALY
numbers do not, by far, represent the total impact on
human health by this global neurotoxicant.
Methylmercury is another neurotoxicant with detailed
dose-response data and exposure information [55], but it
has not been considered in the GBD report. Relying on
recently updated dose-response data, annual costs for
the EU [56] and the US [57, 58] have been estimated at
a total of about $15.6 [$13.8 – $16.9] billion. As the dis-
tribution of methylmercury exposures varies substan-
tially with dietary intakes of predatory fish [59–61],
global costs are difficult to estimate at present.
Used as chemical flame retardants, the polybrominated
diphenyl ethers (PBDEs) have been linked to IQ deficits in
prospective studies of birth cohorts [62–64]. Organophos-
phate pesticides (OPs) may elicit similar deficits [65–67].
Because endocrine disruption is a possible mode of action
for these substances [68], neurotoxicity was included in re-
cent calculations of costs associated with EDC exposures
[69]. In the EU, IQ losses due to PBDEs resulted in eco-
nomic productivity losses of $12.6 [$2.8 – $29.4] billion,
whereas OPs resulted in lost economic productivity of $194
[$62 – $259] billion. In the U.S., where exposures are differ-
ent, similar data suggest losses of $266 [$133 – $367]
billion and $44.7 [$14.6 – $59.5] billion, for PBDEs and
OPs, respectively [39]. These costs thereby total almost
$500 [$200 –$700] billion, a value that corresponds to
about 10 million DALYs (i.e. close to the GBD estimate for
lead alone [3]). These recent studies also calculated add-
itional costs associated with exposure-related increases in
the occurrence of ADHD and autism, but these costs are
smaller and are therefore not considered here.
These four types of neurotoxicants contribute costs that
represent more than 2.5% of the global GDP (Table 1) and
belong to a larger group of twelve neurotoxic substances
found to be convincingly associated with adverse effects
on human brain development [15]. Although neurotoxic
arsenic is a serious water contaminant in many countries
[11, 70], insufficient evidence is available at this time to
calculate costs. Even so, arsenic costs may well be of a
magnitude similar to the one associated with lead expos-
ure. Thus, for most of the other known neurotoxicants,
plausible cost estimates cannot be produced at present
due to insufficient exposure documentation and in some
cases uncertain dose-response relationships, especially at
low exposure levels.
An important reason that DALY calculations for neu-
rotoxicants are seriously underestimated is that they re-
flect costs only for intellectual disabilities, and solely
those attributed to lead exposure [3]. For comparison,
OP exposure is estimated to cause 59,300 cases of intel-
lectual disability in the EU and 7500 cases in the U.S.
[39, 69]. In fact, when compared to the costs linked by
the GBD to intellectual disabilities alone, the costs that
we estimate from OP-associated cognitive dysfunction
were six fold higher in the EU [69] and three-fold higher
in the U.S. [39].
Optimal brain functions, not just the absence of intellec-
tual disabilities, are necessary for health and for productiv-
ity in society, and the brain therefore differs from most
other organ systems, for which minor decrements may be
fully compatible with health [16]. Thus, focusing only on
intellectual disabilities and disregarding less severe cogni-
tive dysfunction results in a substantial underestimation of
the total societal costs due to neurotoxicity.
Air pollution
In regard to ambient air pollution as an environmental
health risk factor, the GBD calculations [3] reported a
total of 74.7 million DALYs lost due to particulate mat-
ter and ozone leading to a crude estimate of $1.1
[0.677–2.7] trillion in annual costs (Table 2). For com-
parison, WHO estimates for particulate matter show 85
million DALYs lost, corresponding to $1.2 [0.74–2.9]
trillion [29]. In both studies, the focus was on pulmonary
disease, lung cancer, and cardiovascular effects.
However, the GBD report [3] ignored several important
outcomes. For example, longitudinal studies of particulate
matter less than 2.5 μm in diameter have linked exposures
during pregnancy to increased incidence of preterm birth
or low birth weight [71]. Such outcomes are associated
with direct medical care costs for the neonate, as well as
long-term costs associated both with medical care and as
a result of lower IQ.
Likewise, cognitive deficits have been linked to local air
pollution both prenatally [72] and at school age [73].
Attribution to specific substances remains somewhat
uncertain due to heterogeneities in the origins of these
conditions and the complex compositions of air pollution
as well as inconsistencies in study designs that also
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contribute to different findings in available studies [74].
Nonetheless, findings from toxicological studies add bio-
logical plausibility and credence to the results from obser-
vational studies [74–76]. Although this evidence has only
recently been systematically evaluated [77], the cost esti-
mates suggest that air pollution likely contributes much
more to the environmental disease burden than summa-
rized by the GBD report [3].
Asbestos may also be considered an ambient air pollu-
tant [78, 79], although the GBD authors regarded it as an
occupational risk factor only. Asbestos-associated cancers
of the lung, mesothelium and other sites are likely under-
estimated for populations in general, and this may also be
true for other adverse outcomes, especially in LMICs [80].
Other substances listed by the GBD report as occupational
hazards may well contribute to community risks as well.
Endocrine disruptors and other environmental hazards
International working groups have assessed environmental
chemicals that are thought to cause disruption of endo-
crine functions, thus leading to a variety of diseases and
dysfunctions [38, 81]. The experts used a modified Delphi
approach as described above to deal with uncertainties
and to estimate minimal societal costs. Although the toxic
mechanism for some chemicals classified as EDCs may be
unknown and may not necessarily reflect interference with
hormonal functions, the working groups scrutinized expo-
sures to EDCs in regard to relevant adverse outcomes. In
addition to cognitive dysfunction, consensus was achieved
for probable (>20%) attribution of chemical exposures in
regard to childhood and adult obesity, testicular cancer,
male infertility and mortality associated with reduced tes-
tosterone, fibroids, and endometriosis [81] – all conditions
that are not usually considered in BoD calculations. Apart
from cognitive deficits, the major estimated costs were as-
sociated with obesity, with one of the phthalates contrib-
uting most of the costs ($20.8 billion) [5].
The total costs of EDC exposures in the EU and the
US have been estimated to be $217 [$110 - $359]
billion [81] and $340 [$0.67 - $612] billion [39], re-
spectively. Converted to DALYs the total costs repre-
sent 4.1[2.1–6.9] million DALYs for the EU countries
and 4.3 [0.84–7.7] million DALYs for the US. These
numbers constitute a minimum, as calculations were
carried out only for substances and outcomes with a
high probability of causation and for which exposure
data were available. Again, these findings indicate that
current estimates of the environmental BoD are much
too low.
Economic impacts have been published for a variety
of additional chemical exposures, most of which are
not yet covered in the GBD (see Additional file 1: Table
S1). However, most calculations identified are based on
a variety of assumptions and cover different age strata
and populations and therefore do not represent a sys-
tematic approach that would be required for calculation
of global burdens of disease. Yet, the calculations illus-
trate the substantial contribution associated with ad-
verse health outcomes and environmental etiologies not
currently considered in the GBD estimates.
Diseases for which environmental cost estimates exist
but are not covered by the 2013 GBD report include child-
hood asthma [57, 82], preterm birth [83], testicular cancer
[84], male factor infertility [84], autism and ADHD [69],
cryptorchidism [84], liver and lung cancer and toxicity
[85], renal toxicity [85], childhood and adult obesity [5,
Table 2 Estimates of economic costs associated with air pollution
Adverse consequence Context Economic cost ($billions) % GDP % of Global GDP
Asthma U.S. [57] 2.33 [0.728–2.5] 0.02 [0.006–0.021] <0.01
EU [82] 1.70 [0.568–1.98] 0.01 [0.003–0.012] <0.01
EU city children [97] 0.151 [0.03–0.3]a <0.01 <0.01
Preterm birth U.S. [98] 4.3 [2.06–8.22] <0.01 <0.01
Cardiovascular EU [99] 37.24 [24.47–49.83]a 0.22 [0.14–0.29] 0.06
All health impacts OECD countries [100] 500 [300–1250] 1.2 [0.7–2.8] 0.8 [0.5–2]
China [100] 483 [300–1200] 8 [5–20] 0.8 [0.5–2]
India [100] 120 [74–300] 7 [4–17] 0.2 [0.1–5]
Sum (OECD, China, India) 1100 [700–2760] 2.2 [1.3–5.4] 1.8 [1.1–4.4]
World (WHO) [52] 1177 [736–2942] 1.9 [1.1–4.6] 1.9 [1.1–4.6]
World (GBD) [3] 1083 [677–2709] 1.7 [1.1–4.3] 1.7 [1.1–4.3]
Base case estimates are presented along with range [low/high end estimates] from sensitivity analysis or 95 CIa. All estimates are given in $2010, a 1.33 rate
change € /$ is used, and for estimates prior to 2010, inflated adjustments are made. OECD estimates are based on DALYs reported for OECD countries (High
Income Countries, HICs), China (Upper Middle Income Country, UMIC), & India (Lower Middle Income Country, LMIC). Our estimates of DALYs for OECD, WHO and
GBD are based on Value of Life Year (VOLY) [50] adjusted to $2010 PPP and for inflation and then adjusted per income group levels from World Bank GNI per
capita in $ppp2010. For consistency we valued OECD DALY estimates based on VOLY instead of using Value of Statistical Life Year (VSL) for mortality costs
(additional 10% for morbidity included) as reported in OECD [100]
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86], adult diabetes [5], fibroids and endometriosis [38],
and coronary heart disease of chemical origin [84, 86].
In addition, important chemical exposures that are
known to be associated with adverse health effects include
a much broader array of industrial chemicals, such as al-
drin [85], bisphenols [5], dichlorodiphenyltrichloroethane
(DDE) [5, 38], lindane [85], organic and inorganic mercury
[56, 57, 85], OPs [69], PBDEs [84] and phthalates [5, 69,
84, 87]. Further, risks associated with exposures to sub-
stances like arsenic and cadmium were considered in the
2013 GBD report [3] only as occupational, although they
also occur in the general environment [7].
As a complement, and in the absence of sufficient
evidence to generate overall chemical-related cost esti-
mates, we used the environmental AFs judged by WHO
experts for a range of relevant diagnoses [29] to calcu-
late approximate DALY burdens and economic costs
(Table 4). We note that several groups of diseases of
major public health significance were judged to cause
very substantial costs in terms of DALYs and economic
expenses. The total annual cost for the groups of dis-
eases selected by the WHO experts was about $4 [2.5–
10.1] trillion, or 260 million DALYs. Although this
DALY estimate is twice as high as the GBD calculation
of 127 million for the environmental BoD [3], the esti-
mates provided by WHO overlap only to a small extent
with the risk factors considered by the GBD authors.
Accordingly, the total environmental BoD would likely
be substantially greater than calculated by either group.
Further, our above compilation of costs due to neuro-
toxic chemicals (Table 1) is substantially higher than
both the GBD estimate for lead exposure and the
WHO calculation for neurobehavioral deficits, and our
toxicology-based results therefore add further to the
total costs.
Implications
Our findings suggest that a revised paradigm is required
for evaluating and prioritizing the environmental contri-
bution to human illness and the associated costs. As an
important requirement for proper assessment of the en-
vironmental BoD, lack of complete documentation
should not be misconstrued to mean that an environ-
mental risk factor has no adverse impact on health [21,
22]. A revised paradigm will have to use systematic,
though less restricted, criteria for causal attribution, as
already recommended by WHO [31]. While this has
been achieved on regional scales in recent studies of
EDCs [38, 39] and methylmercury neurotoxicity [56],
obstacles are likely to occur in generating such analyses
on a global scale due to paucity of exposure data and
difficulties in estimating costs in different settings. Our
approach utilizes both toxicology information and health
economics methods and thereby represents an important
supplement to currently used methods that result in
serious underestimations.
At present, the outcomes and exposures covered by
the literature represent only a small part of the chem-
ical universe and their full spectrum of effects on hu-
man health. Still, the cost estimates add up to sizable
amounts that is similar to the 5.18% of the narrowly de-
fined environmentally-attributable DALYs reported in
the 2013 GBD report [3]. The estimates provided by
WHO from expert opinion suggest that environmental
risks contribute approximately 260 million DALYs or
twice as much as calculated by the GBD authors [29].
Our results are in reasonable agreement with some of
WHO estimates, although the WHO-calculated costs
for neurotoxicity (Table 4) are clearly much too low
(Table 1).
Accordingly, the total cost estimated for specific risk
factors with known toxicology and exposure data were
evaluated at 5.3% of the global GDP (Tables 1, 2 and 3).
Further, the 6.5% estimate from the AFs was obtained by
WHO (Table 4), and the DALY calculations obtained by
the GDB authors correspond to about half as much. As
the risk factors considered by the three different ap-
proaches only partially overlap, the total environmental
BoD costs likely exceed 10% of the global GDP.
Our calculations in terms of the global GDP suggest
that several environmental risk factors represent very
substantial annual losses. The application of different
country-based unit values of DALYs generated detailed
global cost estimates as well as value ranges, although
caution is necessary when interpreting specific results.
Our findings emphasize the need to consider updated
and more comprehensive benefit-cost ratios when apply-
ing cost-effectiveness thresholds commonly used in eco-
nomic evaluations in support of health priority setting
or interventions [88, 89]. The data presented here sug-
gest that environmental chemicals need to be more
highly prioritized.
Of the close to 127 million DALYs attributed by the
GBD report to environmental risks, ambient air pollu-
tion is a main contributor [3]. While this estimate is in
approximate accordance with other calculations, adverse
effects of air pollutants, e.g., on preterm birth and on
brain development were not included. Lead exposure is
also a major contributor due to the association with in-
tellectual disabilities, but the total costs are much higher
than the costs linked to intellectual disabilities only.
Similarly, other developmental neurotoxicants, such as
pesticides, methylmercury, and arsenic, not included in
the GBD, are associated with costs that are at least as
large as those caused by lead alone. Neurodevelopmental
toxicity therefore must be considered a much greater
contributor to the environmental BoD than indicated by
the DALY losses. Our results therefore also suggest
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changes in the focus on environmental health strategies
to protect human health.
While the GBD considered a high body mass index to
be as important a risk factor as all environmental risk
factors combined [3], exposures to phthalates and other
endocrine disruptors represent a substantial attributable
fraction for obesity [5, 90]. Some degree of environmen-
tal causation therefore seems to contribute to high body
mass index as a main risk factor. The same is probably
true for elevated blood pressure [7, 91]. Future calcula-
tions should therefore focus on environmental etiologies,
rather than intermediate stages of the pathogenesis.
A major obstacle in assessing attributable risks from
environmental chemicals is the incomplete documenta-
tion of causal associations and exposure distributions.
Fortunately, techniques are available to overcome these
difficulties [11, 38] so that more representative costs can
be estimated from at least partial documentation,
thereby avoiding the erroneous assumption of zero costs
when the evidence is uncertain [22]. Individual levels of
chemical exposures can often be measured by means of
exposure biomarkers [92], but the current coverage is
patchy, both in regard to substances and populations.
Further, data that represent industrial chemical exposures
outside of Europe and the U.S. are available only from a
small number of countries.
Obtaining better estimates of exposure levels beyond
Europe and North America is a necessary contribution
to the achievement of the Sustainable Development
Goals. For example, hazardous waste sites already
Table 3 Estimates of economic costs associated with EDC exposures in the EU [81] and the US [39]
EDC Adverse consequences Context Economic costs ($millions) % GDP (2010) % of Global GDP
Polybrominated diphenyl
ethers (PBDEs)
Testicular cancer US 81.5 [24.8–109.3] <0.01 <0.01
EU 1100 [416–1100] <0.01 <0.01
Cryptorchidism US 35.7 [NA - NA] <0.01 <0.01
EU 172.6 [155.5–172.6] <0.01 <0.01
Dichlorodiphenyl
trichloroethane (DDE)
Childhood obesity US 29.6 [NA - 57.3] <0.01 <0.01
EU 32.7 [NA - 114.8] <0.01 <0.01
Adult diabetes US 1800 [NA – 13,500] <0.01 [NA - 0.08] <0.01
EU 1100 [NA – 22,065] <0.01 [NA - 0.13] <0.01
Fibroids US 259 [NA - NA] <0.01 <0.01
EU 216.8 [NA - NA] <0.01 <0.01
Di-2-ethylhexyl phthalate Adult obesity US 1700 [NA - NA] 0.011 <0.01
EU 20,800 [NA - NA] 0.12 <0.01
Adult diabetes US 91.4 [NA - NA] <0.01 <0.01
EU 807.2 [NA - NA] <0.01 <0.01
Endometriosis US 47,000 [NA - NA] 0.32 <0.01
EU 1700 [NA - NA] 0.01 <0.01
Bisphenol A Childhood obesity US 2400 [NA - NA] 0.02 <0.01
EU 2000 [NA - NA] 0.02 <0.01
Benzyphtalates &
butylphalates
Male infertility resulting in
Increasesed ART
US 2500 [NA - NA] 0.02 <0.01
EU 6300 [NA - NA] 0.04 0.01
Phtalates Low testoterone and increased
early mortality
US 8800 [NA - NA] 0.06 0.012
EU 10,600 [NA - NA] 0.05 0.012
Multiple exposures Attention deficit hyperactivity
disorder (ADHD)
US 698 [568–1950] <0.01 [<0.01–0.011] <0.01
EU 3056 [1600–3800] 0.014 [<0.01–0.017] <0.01
Autism US 1984 [803–4100] 0.014 [<0.01–0.024] <0.01
EU 352 [105–530] <0.01 <0.01
All compounds
included
US 340,000 [668–612,000] 2.33 [<0.01–3.53] 0.54 [<0.01 0.96]
EU 217,000 [110,049–359,239] 1.2 [0.75–2.12] 0.34 [0.17–0.57]
Sum 557,000 [110,707–971,239] 1.8 [0.3–3.07] 0.88 [0.17–1.54]
NA: Not available
Base case estimates are presented along with ranges [Low end and High end estimates] from sensitivity analyses, when available
All estimates are given in $2010, for EU a 1.33 rate change € /$ is used, and for estimates prior to 2010, inflated adjustments are made
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constitute a main source of exposure to toxic agents in
LMICs [93, 94]. The OECD estimates that, by 2030, the
LMICs will comprise the leading sites for chemical
manufacture and use [95], while infrastructures to pro-
tect public health and the environment may be insuffi-
cient [96]. Simple extrapolation from the American or
European experience to estimate global attributable
burdens would then be inappropriate. In addition, re-
search must continue to better elaborate the effects of
industrial chemicals in LMICs with weaker regulatory
infrastructure to prevent uncontrolled exposures to
vulnerable population groups, and where greater effects
may ensue than those identified in industrialized coun-
tries. As a further consideration, the recent estimate of
global costs of childhood lead exposure assumes that
current PPP data could correct for differences in life-
time economic productivity, and the impact of IQ on
economic productivity [53]. Given the much higher
rates of growth in GDP per capita in some LMICs, es-
pecially in China, India and several countries of South-
east Asia, annual productivity gains are almost certainly
higher than in industrialized countries. Consequently,
PPP correction yields an underestimate of the true cost
of childhood exposure to lead and other neurotoxi-
cants. Given that LMICs vary in their health care deliv-
ery systems, estimating direct costs of medical care due
to conditions that result from industrial chemical haz-
ards cannot rely on simple extrapolation from a single
country’s experience to an entire continent. Still, these
uncertainties should not prevent prudent judgment and
proper evaluation of the costs to society due to the en-
vironmental BoD.
The human capital approach that we used enabled the
estimation of indirect costs, such as lost lifetime earn-
ings, along with direct costs of medical treatment [42,
43]. Yet intangible costs, such as the value to an individ-
ual avoiding pain and suffering, may also be substantial
[91]. Willingness To Pay (WTP) methods have been de-
veloped to capture these values. Thus, DALY values
imply a WTP for disability prevention. Insofar as great
care is taken to avoid double counting, WTP and COI
methods can be complementary and may be leveraged
to better quantify the complete societal value of preven-
tion (Fig. 1).
The importance of these issues goes beyond the re-
search community and health care institutions. Deci-
sions made by health ministries regarding prevention
are generally separate from the investments needed to
prevent chronic conditions as by-products of industrial
chemical exposures. Thus, health protection and health
care decisions are usually taken without regard to ne-
cessary environmental regulation or modification in
manufacturing, energy production, transportation, and
other practices. When policy makers decide whether to
limit effects of industrial chemical exposures, the nar-
row costs to industry are often presented as reasons
not to proceed with protections to human health [96].
Concerns about costs to the private sector can appear
particularly acute in the industrializing world context,
where added emphasis is placed on accelerated
Table 4 Environmental burdens of disease in terms of DALYs, economic value, and percent of GDP for major health outcomes
based on attributable risks derived by WHO [29]a
Disease DALYs (% fraction of
total burden of disease
in DALYs)
Environmental AF (%) DALYs due to environmental
risk factors
Economic cost
($billions)
% of Global GDP
Respiratory diseases
Asthma 25,202,418 (0.9) 44 (26–53) 11,055,150 200 [124–500] 0.3 [0.2–0.8]
Chronic obstructive
pulmonary disease
92,376,604 (3.4) 35 (20–48) 32,280,160 400 [250–1000] 0.6 [0.4–1.5]
Lower respiratory
infections
146,863,685 (5.4) 35 (27–41) 51,752,605 530 [330–1320] 0.8 [0.5–2.1]
Cancers
Lung cancer 38,535,303 (1.4) 36 (17–52) 13,902,105 285 [180–720] 0.5 [0.3–1.1]
Other cancers 185,421,704 (6.8) 16 (7–41) 31,047,781 715 [450–1800] 1.1 [0.7–2.8]
Cardiovascular diseases
Ischemic heart diseases 165,717,210 (6.0) 35 (26–46) 58,561,915 1065 [670–2660] 1.8 [1.1–4.2]
Stroke 141,348,082 (5.2) 42 (24–53) 58,985,984 843 [527–2108] 1.3 [0.8–3.3]
Neuropsychiatric diseases
Childhood behavioral
disorders
6,208,771 (0.22) 12 (3–36) 742,156 12 [8–30] 0.02 [0.01–0.05]]]
Total 258,327,866 4050 [2500–10,140] 6.5 [4–15.8]
aTotal DALYs, 2,743,857,491 (2012 values); Breakdown of DALYS for LMICs and HICs from WHO supplement [29]
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economic growth that can induce further investments
in health and other societal priorities. The present
study illustrates that the current DALY approach is in-
sufficient to estimate the total environmental BoD that
would be of importance in generating useful guidance
for policy decisions. Our results illustrate that a more
comprehensive assessment of costs, also for dysfunc-
tions and other outcomes less serious than mortality
and diagnosed morbidity, is both necessary and
feasible.
For proper evaluation of the environmental BoD, a
new paradigm is needed to better inform decisions by
clinicians, public health officials and regulatory agen-
cies about the likely scope of disease and dysfunction
associated with industrial chemicals. Recent studies
have demonstrated that major obstacles in assessing
attributable risks from environmental chemicals, such
as the incomplete documentation of causal associa-
tions and exposure distributions, can be overcome
[29, 38, 56]. Hence, while uncertainties in causation
and distribution of environmental exposures will re-
main, they should not prevent realistic calculations of
estimated disease burdens due to environmental risks.
Our toxicology-economics approach can add to the
proper recognition of preventable risk factors in both
rich and poor countries alike as a necessary contribu-
tion to the achievement of the Sustainable Develop-
ment Goals.
Conclusions
The most recent assessment of Disability-Adjusted Life
Year (DALY) losses estimated that environmental caus-
ation contributes only 5.18% of the total disease bur-
den. However, these estimates ignore risks that are
considered uncertain and exclude subclinical condi-
tions, although the costs are certainly not zero. We re-
lied on health economics methods to estimate societal
costs associated with adverse outcomes of exposures to
environmental chemicals. We highlight substances such
as mercury, pesticides, brominated diethyl ethers, and
several endocrine disrupting chemicals as serious health
hazards that need to be confronted. Our results show
that functional deficits, especially regarding cognition,
greatly add to the total environmental Burden of Dis-
ease (BoD) and that total costs are substantially higher
than those calculated in terms of the DALY losses that
are linked to specific medical diagnoses. We also
emphasize that environmental BoD assessments are easily
underestimated, especially when focusing only on risk fac-
tors with detailed documentation, and when ignoring ad-
verse effects beyond specific disease risks and mortality.
Calculations to derive exposure-related health costs for
comparison with DALY estimates should be encouraged
to obtain more comprehensive and valid conclusions on
the environmental BoD. Achievement of the Sustainable
Development Goals will require this recognition of envir-
onmental risk factors as major contributors to human dys-
function, disease, and mortality in both rich and poor
countries alike.
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